ConductScience.org, home

Paper33799685

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

Carnevale-Schianca F and 26 others. J Clin Med, 2021. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Papers, record 33799685. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33799685

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
PubMed
Journal
J Clin Med
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.96
iCite
Revised in PubMed
2021-04-08
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Carnevale-Schianca FFabrizio
2Caravelli DDaniela
3Gallo SSusannahttps://orcid.org/0000-0002-7993-6068
4Becco PPaolo
5Paruzzo LLuca
6Poletto SStefano
7Polo AAlessandra
8Mangioni MMonica
9Salierno MMilena
10Berger MMassimo
11Pessolano RRosanna
12Saglio FFrancesco
13Gottardi DDaniela
14Rota-Scalabrini DDelia
15Grignani GGiovannihttps://orcid.org/0000-0001-5515-569X
16Fizzotti MMarco
17Ferrero IIvana
18Frascione PMMPio Manlio Mirko
19D'Ambrosio LLorenzohttps://orcid.org/0000-0003-3294-8819
20Gaidano VValentina

Source PubMed

See all 27 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Ricerca DS-321FPRC ONLUS-5x1000 ,Ministero della Salute 2015PubMed
ADISCO Sezione PiemonteADISCO Sezione PiemontePubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02300571
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128249141Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.N Engl J Med2017https://conductscience.org/library/papers/28249141PubMed
225667989Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.Biol Blood Marrow Transplant2015https://conductscience.org/library/papers/25667989PubMed
323478054Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.J Clin Oncol2013https://conductscience.org/library/papers/23478054PubMed
429567707CAR T cell immunotherapy for human cancer.Science2018https://conductscience.org/library/papers/29567707PubMed
526723083
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Lancet Oncol2016https://conductscience.org/library/papers/26723083PubMed
628039079
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Biol Blood Marrow Transplant2017https://conductscience.org/library/papers/28039079PubMed
729385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
820124511High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Blood2010https://conductscience.org/library/papers/20124511PubMed
924958183Current and emerging strategies for the prevention of graft-versus-host disease.Nat Rev Clin Oncol2014https://conductscience.org/library/papers/24958183PubMed
1025316679Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Blood2014https://conductscience.org/library/papers/25316679PubMed
1126970381Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.Biol Blood Marrow Transplant2016https://conductscience.org/library/papers/26970381PubMed
1227870568Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.J Clin Oncol2017https://conductscience.org/library/papers/27870568PubMed
1323200544Have we made progress in the treatment of GVHD?Best Pract Res Clin Haematol2012https://conductscience.org/library/papers/23200544PubMed
1430709437
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Lancet Haematol2019https://conductscience.org/library/papers/30709437PubMed
1519695955
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Lancet Oncol2009https://conductscience.org/library/papers/19695955PubMed
1621464398Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.J Clin Oncol2011https://conductscience.org/library/papers/21464398PubMed
1725682602Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.Haematologica2015https://conductscience.org/library/papers/25682602PubMed
1816338616National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.Biol Blood Marrow Transplant2005https://conductscience.org/library/papers/16338616PubMed
1929040031
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
J Clin Oncol2017https://conductscience.org/library/papers/29040031PubMed
2032227211Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.Blood Adv2020https://conductscience.org/library/papers/32227211PubMed

See all 62 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
41114809Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion.Ann Hematol2025https://conductscience.org/library/papers/41114809PubMed
40141738Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis After Peripheral Blood Stem Cell HLA Identical Transplantation in Patients with Lymphoma: A Prospective Observational Study.Life (Basel)2025https://conductscience.org/library/papers/40141738PubMed
39257713
Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant.
Int J Hematol Oncol Stem Cell Res2024https://conductscience.org/library/papers/39257713PubMed
38930096
Optimizing Outcomes in Mismatched Unrelated Donor Allogeneic Transplantation: Post-Transplant Cyclophosphamide's Dual Impact on Graft versus Host Disease Incidence and Overall Survival: Retrospective Analysis on Behalf of Polish Adult Leukemia Group.
J Clin Med2024https://conductscience.org/library/papers/38930096PubMed
38615143
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Bone Marrow Transplant2024https://conductscience.org/library/papers/38615143PubMed
38545096Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.Front Immunol2024https://conductscience.org/library/papers/38545096PubMed
37261557Posttransplant cyclophosphamide beyond haploidentical transplantation.Ann Hematol2024https://conductscience.org/library/papers/37261557PubMed
37140099Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.Clin Transl Med2023https://conductscience.org/library/papers/37140099PubMed
35930118Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.Int J Hematol2022https://conductscience.org/library/papers/35930118PubMed
35066570Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.Bone Marrow Transplant2022https://conductscience.org/library/papers/35066570PubMed
34586587A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.Int J Hematol2022https://conductscience.org/library/papers/34586587PubMed
34425261Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.Transplant Cell Ther2021https://conductscience.org/library/papers/34425261PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
HLA-DQB13119PubTator's text mininghttps://conductscience.org/library/genes/3119NCBI Gene
HLA-DRB13123PubTator's text mininghttps://conductscience.org/library/genes/3123NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33799685

GET https://conductscience.org/api/papers/v1/33799685/authors?page=2